Fig. 4: ICD and cGAS-STING pathway activation in residual tumors after treatments. | Cell Death & Disease

Fig. 4: ICD and cGAS-STING pathway activation in residual tumors after treatments.

From: Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma

Fig. 4: ICD and cGAS-STING pathway activation in residual tumors after treatments.The alternative text for this image may have been generated using AI.

A, B Western blotting was used to measure the expression of ICD proteins (ATP, CALR, HMGB1). C, D Flow cytometry was applied to assess the percentage of mature dendritic cells (CD80+CD86+ DC cells). E, F Western blotting was used to evaluate the expression of cGAS-STING pathway proteins (cGAS, STING, p-TBK1, and p-IRF3). G–J qRT-PCR was performed to measure the expression of TNF-α, CXCL9, CXCL10, and IFN-β in residual tumors. K–N ELISA was applied to assess the levels of TNF-α, CXCL9, CXCL10, and IFN-β in the mice plasma. n = 6 in each group. Error bars represent standard deviation. ***p < 0.001. ICD immunogenic cell death, iRFA incomplete radiofrequency ablation, CTLA-4 cytotoxic T lymphocyte antigen-4, qRT-PCR quantitative real-time polymerase chain reaction assay, ELISA enzyme-linked immunosorbent assay.

Back to article page